Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.

Biotechnology

Health Care

Life Sciences

Therapeutics

Ottimo Pharma

David Epstein

Rick Anderson

Katherine Bell-McGuinn

Spencer Fisk

Ling Zeng

Ottimo Pharma

Org chart

Teams

Offices

Ottimo Pharma

Org chart

Teams

Offices

Related companies